IL314371A - Vaccines against hepatitis B virus - Google Patents

Vaccines against hepatitis B virus

Info

Publication number
IL314371A
IL314371A IL314371A IL31437124A IL314371A IL 314371 A IL314371 A IL 314371A IL 314371 A IL314371 A IL 314371A IL 31437124 A IL31437124 A IL 31437124A IL 314371 A IL314371 A IL 314371A
Authority
IL
Israel
Prior art keywords
hbv
arenavirus
protein
orf
infectious
Prior art date
Application number
IL314371A
Other languages
English (en)
Hebrew (he)
Inventor
Thomas Monath
Katherine Cohen
Vera Baumgartl-Strasser
Original Assignee
Hookipa Biotech Gmbh
Thomas Monath
Katherine Cohen
Baumgartl Strasser Vera
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh, Thomas Monath, Katherine Cohen, Baumgartl Strasser Vera filed Critical Hookipa Biotech Gmbh
Publication of IL314371A publication Critical patent/IL314371A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL314371A 2015-11-04 2016-11-03 Vaccines against hepatitis B virus IL314371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250639P 2015-11-04 2015-11-04
PCT/EP2016/076591 WO2017076988A1 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Publications (1)

Publication Number Publication Date
IL314371A true IL314371A (en) 2024-09-01

Family

ID=57249796

Family Applications (2)

Application Number Title Priority Date Filing Date
IL314371A IL314371A (en) 2015-11-04 2016-11-03 Vaccines against hepatitis B virus
IL259077A IL259077B2 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL259077A IL259077B2 (en) 2015-11-04 2016-11-03 Vaccines against hepatitis b virus

Country Status (20)

Country Link
US (2) US11214598B2 (enExample)
EP (2) EP3371316B1 (enExample)
JP (3) JP6914950B2 (enExample)
KR (2) KR102832178B1 (enExample)
CN (2) CN108779472B (enExample)
AU (3) AU2016348675B2 (enExample)
CA (1) CA3003557A1 (enExample)
DK (1) DK3371316T3 (enExample)
ES (1) ES2934698T3 (enExample)
FI (1) FI3371316T3 (enExample)
HR (1) HRP20221474T1 (enExample)
HU (1) HUE060648T2 (enExample)
IL (2) IL314371A (enExample)
LT (1) LT3371316T (enExample)
MX (2) MX2018005569A (enExample)
PL (1) PL3371316T3 (enExample)
PT (1) PT3371316T (enExample)
SG (1) SG11201803474UA (enExample)
SI (1) SI3371316T1 (enExample)
WO (1) WO2017076988A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103255169A (zh) 2007-12-27 2013-08-21 苏黎士大学 复制缺陷型沙粒病毒载体
ES2868427T3 (es) 2013-12-03 2021-10-21 Hookipa Biotech Ag Vacunas contra el CMV
EP3218504B1 (en) * 2014-11-13 2020-07-22 Université de Genève Tri-segmented arenaviruses as vaccine vectors
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CA3003557A1 (en) * 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
US11266727B2 (en) 2015-11-12 2022-03-08 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
JP2022010187A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
JP2022010188A (ja) * 2017-02-03 2022-01-14 株式会社三洋物産 遊技機
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CA3143680A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
CA3143421A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
IL315295A (en) 2019-09-30 2024-10-01 Gilead Sciences Inc Hbv vaccines and methods treating hbv
US20220380805A1 (en) * 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
EP4445902A3 (en) 2019-12-24 2024-12-18 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
KR102375703B1 (ko) 2020-07-28 2022-03-17 경북대학교 산학협력단 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템
WO2022200373A2 (en) 2021-03-23 2022-09-29 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
WO2022226242A1 (en) * 2021-04-21 2022-10-27 La Jolla Institute For Immunology Engineered arenavirus glycoprotein compositions, methods and use thereof
CN113201051B (zh) * 2021-04-27 2022-08-02 复旦大学 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH1084967A (ja) * 1996-09-19 1998-04-07 Fujirebio Inc Ｂ型肝炎のｅ抗原
EP2360174B1 (en) * 1998-12-04 2014-04-09 Biogen Idec MA Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
FR2803599B1 (fr) * 2000-01-06 2004-11-19 Inst Nat Sante Rech Med Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
US20100183652A1 (en) * 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
EP1888622A1 (en) 2005-05-23 2008-02-20 Oxxon Therapeutics Ltd. Compositions for inducing an immune response against hepatitis b
CN101037476A (zh) * 2006-03-15 2007-09-19 复旦大学 一种用于制备抗体化乙肝疫苗的融合蛋白及其载体
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
WO2008083174A2 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
CN103255169A (zh) * 2007-12-27 2013-08-21 苏黎士大学 复制缺陷型沙粒病毒载体
NZ598000A (en) 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
PH12013501683A1 (en) * 2011-02-12 2019-07-17 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis b infection
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
IN2014DN06118A (enExample) 2012-01-24 2015-08-14 Sanford Res Usd
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
ES2868427T3 (es) 2013-12-03 2021-10-21 Hookipa Biotech Ag Vacunas contra el CMV
US10342861B2 (en) 2014-05-27 2019-07-09 University Of Rochester Arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
JP6875274B6 (ja) 2014-09-22 2021-06-30 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ピチンデウイルスのリバースジェネティクス系及び使用方法
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
EP3218504B1 (en) * 2014-11-13 2020-07-22 Université de Genève Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CA2987155A1 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
WO2017068190A1 (en) 2015-10-23 2017-04-27 Institut Pasteur Recombinant mopeia virus and vaccine platform
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
US11266727B2 (en) 2015-11-12 2022-03-08 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
NZ788311A (en) 2016-05-18 2025-11-28 Univ Basel Tri-segmented pichinde viruses as vaccine vectors
AU2017353443B2 (en) 2016-11-04 2024-11-14 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en) 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
PL3371316T3 (pl) 2023-02-13
AU2023200108B2 (en) 2025-08-28
MX2018005569A (es) 2018-12-19
US11214598B2 (en) 2022-01-04
JP6914950B2 (ja) 2021-08-11
AU2016348675A1 (en) 2018-05-17
US20220073568A1 (en) 2022-03-10
BR112018009032A8 (pt) 2019-02-26
IL259077B2 (en) 2024-12-01
IL259077B1 (en) 2024-08-01
CN115948467A (zh) 2023-04-11
SI3371316T1 (sl) 2023-02-28
NZ781654A (en) 2025-06-27
NZ741950A (en) 2023-10-27
KR20180082485A (ko) 2018-07-18
KR102832178B1 (ko) 2025-07-11
MX2023013140A (es) 2023-11-28
HRP20221474T1 (hr) 2023-01-06
JP7777907B2 (ja) 2025-12-01
KR20250107977A (ko) 2025-07-14
SG11201803474UA (en) 2018-05-30
EP3371316A1 (en) 2018-09-12
JP2021182922A (ja) 2021-12-02
AU2025271193A1 (en) 2026-01-15
WO2017076988A1 (en) 2017-05-11
HK1255847A1 (en) 2019-08-30
EP3371316B1 (en) 2022-10-19
US20180319845A1 (en) 2018-11-08
AU2016348675B2 (en) 2022-11-17
AU2023200108A1 (en) 2023-02-16
FI3371316T3 (fi) 2023-01-13
JP2018536433A (ja) 2018-12-13
IL259077A (en) 2018-06-28
JP2024010027A (ja) 2024-01-23
CN108779472A (zh) 2018-11-09
ES2934698T3 (es) 2023-02-24
DK3371316T3 (da) 2023-01-23
HUE060648T2 (hu) 2023-04-28
PT3371316T (pt) 2022-11-17
CA3003557A1 (en) 2017-05-11
CN108779472B (zh) 2022-09-09
LT3371316T (lt) 2022-11-25
BR112018009032A2 (pt) 2018-11-06
EP4177348A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
JP7777907B2 (ja) Ｂ型肝炎ウイルスに対するワクチン
JP7551157B2 (ja) Ｈｉｖワクチン接種および免疫療法
US11554169B2 (en) CMV vaccines
JP7254018B2 (ja) ワクチンベクターとしての三セグメントピチンデウイルス
CN107921117A (zh) Hpv疫苗
TW201734208A (zh) Ｈｂｖ聚合酶突變體
HK40093198A (en) Vaccines against hepatitis b virus
HK40090610A (zh) 针对乙型肝炎病毒的疫苗
HK1255847B (en) Vaccines against hepatitis b virus
NZ741950B2 (en) Vaccines against hepatitis b virus
HK1263252A1 (en) Vaccines against hepatitis b virus
HK1263252B (en) Vaccines against hepatitis b virus
BR122024003112A2 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado
BR122024003112B1 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, uso de vetor viral, ácido nucleico isolado
BR112018009032B1 (pt) Vetor viral de arenavírus infeccioso, composição farmacêutica ou imunogênica ou vacina, uso de um vetor viral, ácido nucleico isolado e uso do ácido nucléico